Table 2.
Patient laboratory and cGvHD characteristics at sample.
| Retrospective patient data set | Prospective, newly-diagnosed cGvHD | |||
|---|---|---|---|---|
| Characteristics | All patients | cGvHDa | Non-cGvHDa | |
| n = 63 | n = 35 | n = 28 | n = 7 | |
| Post-transplant interval, days Median (and range) | 475 (131–3,445) | 570 (131–3,445) | 326 (189–2,065) | 266 (177–561) |
| White blood count at sample, cells/μL Median (and range) | 6.3 (2.0–11.7) | 7.1 (2.0–11.5) | 5.7 (2.4–11.7) | 6.0 (2.2–9.7) |
| Differential, neutrophil, % Median (and range) | 61.1 (3.8–94.2) | 73.2 (39.8–94.2) | 52.2 (3.8–82.7) | 59.8 (5.4–90.5) |
| Differential, lymphocyte, % Median (and range) | 25.2 (2.9–85.1) | 20 (2.9–49.9) | 34.8 (8.6–85.1) | 26.3 (3.0–84.9) |
| Differential, monocyte, % Median (and range) | 8.9 (1.1–18.3) | 7.8 (1.1–15.4) | 9.8 (3–18.3) | 9.0 (1.9–17.1) |
| Chronic GvHD at sample, n (%) | ||||
| None | 26 (41.3) | 0 | 26 (92.9) | 0 |
| De novo | 21 (33.3) | 20 (57.1) | 1 (3.6) | 2 (28.6) |
| Mild/moderate/severe | 10/10/1 | 9/10/1 | 1/0/0 | 0/2/0 |
| Active/inactive | 20/1 | 20/0 | 0/1a | 0/2 |
| Interrupted | 7 (11.1) | 6 (17.1) | 1 (3.6) | 5 (71.4) |
| Mild/moderate/severe | 1/6/0 | 0/5/0 | 1/0/0 | 0/5/0 |
| Active/inactive | 6/1 | 5/0 | 0/1a | 0/5 |
| Progressive | 9 (14.3) | 9 (25.7) | 0 | 0 |
| Mild/moderate/severe | 0/7/2 | 0/7/2 | 0/0/0 | 0/0/0 |
| Active/inactive | 9/0 | 9/0 | 0 | 0 |
| Immunosuppression | ||||
| None | 26 (41.3) | 0 | 26 (92.9) | 7b |
| One | 12 (19.0) | 10 (28.6) 2 (7.1)a | 0 | |
| Two | 20 (31.7) | 20 (57.1) | 0 | 0 |
| Three or >three | 5 (7.9) | 5 (14.3) | 0 | 0 |
a
2 patients with a history of mild severity cGvHD who were weaned from immunosuppressive medications yet maintained on 5mg every-other-day of prednisone for N180 days at the time of sample acquisition were considered non-GvHD.
b
All patients had peripheral blood sampling for gene expression prior to initiating immunosuppression.